Illuminate PD1/PD-L1 Interactions:

Explore immune checkpoint activation in situ

Introducing Naveni™ PD1/PD-L1 Atto 647N

Unlocking the potential of immune checkpoint inhibition therapy calls for precise patient stratification 1-3. While PD-L1 is a commonly used biomarker, its correlation with immunotherapy outcomes isn’t always linear3. Addressing this challenge, Navinci expands its portfolio to unravel PD1 signaling, introducing the groundbreaking fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N.

With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of immune checkpoint activation.

If you prefer to detect PD1/PD-L1 using bright-field, we have you covered with our chromogenic assays. Choose from our range of assays to suit your specific research needs and explore the PD1 signaling pathway.

Download white paper: Identifying PD-1/PD-L1 interactions  –  Implications for clinical research and ICI patient stratification(pdf)

Our PD1 products

The Naveni PD1/PD-L1 kits are based on our proprietary NaveniTM Proximity Ligation Technology. The kits include two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct dot. Naveni PD1/PD-L1 Atto647N is compatible with IF co-staining.

Visualize PD1/PD-L1 interaction in the tumor microenvironment

Images show Non-small-cell lung cancer samples positive and negative for the PD1/PD-L1 interaction (magenta). Tumor tissue visualized by cytokeratin co-staining (yellow). 

Detect PD1/PD-L1 interaction in tumor tissues

PD1/PD-L1 interaction - Tonsil
PD1/PD-L1 interaction - Pancreatic adenocarcinoma
PD1/PD-L1 interaction - Squamous cell lung carcinoma
PD1/PD-L1 interaction - colon adenocarcinoma

Study phosphorylated PD1

Protein post-translational modifications (PTM): Proximity Ligation assay for detection of phosphorylated PD1
Phosphorylated PD1 - Tonsil
Naveni pY PD1 staining of pPD1 in tonsil tissue
Immunohistochemistry staining of pPD1 in the same tonsil tissue

Expert opinion

There is a strong need for running this kind of assay on case cohorts treated with anti-PD1 or anti-PDL1 and studied for the expression of the single markers. The detection of the interaction could actually improve the predictive power of tissue-based target assessment assays.

Professor Claudio Tripodo at the University of Palermo and IFOM (AIRC Institute of Molecular Oncology), and user of our Naveni™ PD1/PD-L1 HRP


1. Pu Y, Ji Q. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Front Immunol. 2022 May 3;13:874589. DOI:10.3389/fimmu.2022.874589

2. Robert C, A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11: 3801​. DOI:10.1038/s41467-020-17670-y

3. Sánchez-Magraner L, et al. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res. 2020 Oct 1;80(19):4244-4257​. DOI:10.1158/0008-5472.can-20-1117